Shay Capital’s Viking Therapeutics VKTX Stock Holding History

Shay Capital’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-15,000	Closed	-$950K	–	440
2024 Q3	$950K	Buy	+15,000	New	+$880K	0.13%	99

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Shay Capital's VKTX Position: Q2 2026 in Review

Shay Capital sold out of Viking Therapeutics (VKTX) in Q2 2026, closing a stake of 16,500 shares — an estimated $533K sold.

Shay Capital first reported a position in VKTX in Q2 2023 and held it in 8 quarters. The position peaked at $2.5M in Q2 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Shay Capital reported no remaining Viking Therapeutics position as of Q2 2026 after selling out during the quarter.
Shay Capital sold 16,500 Viking Therapeutics shares in Q2 2026, an estimated $533K.
Shay Capital first reported a position in Viking Therapeutics in Q2 2023 and held it in 8 quarters.
Shay Capital's Viking Therapeutics position peaked at $2.5M in Q2 2024.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Shay Capital's 13F filing for Q2 2026, filed 14 Aug 2026.